Role of metabolism in drug development: In vitro studies
Značaj izučavanja metabolizma u razvoju novih lekova - in vitro pristup
2010
Authors
Rakić-Ignjatović, AnitaMiljković, Branislava
Ilić, Marija
Pokrajac, Milena
Prostran, Milica
Article (Published version)
Metadata
Show full item recordAbstract
In recent years there has been a significant paradigm shift in pre-clinical drug metabolism studies. Most importantly, this has included a reduced reliance on animal models and increased use of human tissues (i.e. human liver microsomes and other subcellular fractions, primary culture of human hepatocytes, recombinant human enzymes/transgenic cell lines). During the pre-clinical phase of drug development such studies assess the metabolic stability, reaction phenotyping (elucidation of specific enzyme(s) involved in phase I and II metabolism), metabolic fingerprinting (identification and structural determination of the metabolic end products) and drug interaction issues pertaining to enzyme inhibition and induction. Such studies are now increasingly being used for qualitative and quantitative prediction of drug biotransformation in humans and in the identification of likely determinants of metabolism following drug administration to humans, including possible drug interactions. Results ...from a multitude of such experiments help in identifying/optimizing a lead compound and rejecting compounds that are likely to be problematic with regards to causing toxicity or adverse drug-drug interactions. Therefore, well designed in vitro methodologies are vital to reducing the number of human trials during the late stages of drug development.
Upotreba eksperimentalnih životinja i in vitro modela životinjskog porekla u pretkliničkim studijama metabolizma lekova je u velikoj meri potisnuta in vitro eksperimentalnim modelima poreklom od humanih tkiva. Danas se najviše koriste komercijalno dostupni preparati ljudske jetre, kao što su rekombinantni enzimi/transgenske ćelijske linije, subcelularne frakcije (mikrozomi, citozol i S9 frakcija) i primarni hepatociti. Primenom ovih modela u toku pretkliničke faze razvoja novog leka ispituje se stepen metaboličke transformacije leka, vrši se fenotipizacija metaboličkih reakcija (identifikacija specifičnog/ih enzima uključenih u I i II fazu metabolizma leka), određivanje metaboličkog profila (metabolic fingerprinting - identifikacija i određivanje strukture krajnjih produkata metabolizma leka) i razmatra se potencijal za stupanje u interakcije sa drugim lekovima, sa aspekta inhibicije i indukcije metaboličkih enzima. Primena in vitro - in vivo korelacije uz dobro razumevanje farmakokine...tičkih principa omogućava predviđanje metabolizma i interakcija lekova in vivo na osnovu dobijenih in vitro podataka. Rezultati brojnih in vitro eksperimenata imaju značajnu ulogu u identifikaciji/optimizaciji vodećeg kandidata za novi lek. Dobro dizajnirane in vitro studije omogućavaju smanjenje broja kliničkih ispitivanja kod ljudi, koja se sprovode u kasnijim fazama razvoja leka.
Keywords:
metabolism / in vitro models / drug interactions / in vitro-in vivo extrapolation / metabolizam / in vitro modeli / interakcije lekova / in vitro - in vivo ekstrapolacijaSource:
Arhiv za farmaciju, 2010, 60, 4, 353-372Publisher:
- Savez farmaceutskih udruženja Srbije, Beograd
Collections
Institution/Community
PharmacyTY - JOUR AU - Rakić-Ignjatović, Anita AU - Miljković, Branislava AU - Ilić, Marija AU - Pokrajac, Milena AU - Prostran, Milica PY - 2010 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1448 AB - In recent years there has been a significant paradigm shift in pre-clinical drug metabolism studies. Most importantly, this has included a reduced reliance on animal models and increased use of human tissues (i.e. human liver microsomes and other subcellular fractions, primary culture of human hepatocytes, recombinant human enzymes/transgenic cell lines). During the pre-clinical phase of drug development such studies assess the metabolic stability, reaction phenotyping (elucidation of specific enzyme(s) involved in phase I and II metabolism), metabolic fingerprinting (identification and structural determination of the metabolic end products) and drug interaction issues pertaining to enzyme inhibition and induction. Such studies are now increasingly being used for qualitative and quantitative prediction of drug biotransformation in humans and in the identification of likely determinants of metabolism following drug administration to humans, including possible drug interactions. Results from a multitude of such experiments help in identifying/optimizing a lead compound and rejecting compounds that are likely to be problematic with regards to causing toxicity or adverse drug-drug interactions. Therefore, well designed in vitro methodologies are vital to reducing the number of human trials during the late stages of drug development. AB - Upotreba eksperimentalnih životinja i in vitro modela životinjskog porekla u pretkliničkim studijama metabolizma lekova je u velikoj meri potisnuta in vitro eksperimentalnim modelima poreklom od humanih tkiva. Danas se najviše koriste komercijalno dostupni preparati ljudske jetre, kao što su rekombinantni enzimi/transgenske ćelijske linije, subcelularne frakcije (mikrozomi, citozol i S9 frakcija) i primarni hepatociti. Primenom ovih modela u toku pretkliničke faze razvoja novog leka ispituje se stepen metaboličke transformacije leka, vrši se fenotipizacija metaboličkih reakcija (identifikacija specifičnog/ih enzima uključenih u I i II fazu metabolizma leka), određivanje metaboličkog profila (metabolic fingerprinting - identifikacija i određivanje strukture krajnjih produkata metabolizma leka) i razmatra se potencijal za stupanje u interakcije sa drugim lekovima, sa aspekta inhibicije i indukcije metaboličkih enzima. Primena in vitro - in vivo korelacije uz dobro razumevanje farmakokinetičkih principa omogućava predviđanje metabolizma i interakcija lekova in vivo na osnovu dobijenih in vitro podataka. Rezultati brojnih in vitro eksperimenata imaju značajnu ulogu u identifikaciji/optimizaciji vodećeg kandidata za novi lek. Dobro dizajnirane in vitro studije omogućavaju smanjenje broja kliničkih ispitivanja kod ljudi, koja se sprovode u kasnijim fazama razvoja leka. PB - Savez farmaceutskih udruženja Srbije, Beograd T2 - Arhiv za farmaciju T1 - Role of metabolism in drug development: In vitro studies T1 - Značaj izučavanja metabolizma u razvoju novih lekova - in vitro pristup VL - 60 IS - 4 SP - 353 EP - 372 UR - https://hdl.handle.net/21.15107/rcub_farfar_1448 ER -
@article{ author = "Rakić-Ignjatović, Anita and Miljković, Branislava and Ilić, Marija and Pokrajac, Milena and Prostran, Milica", year = "2010", abstract = "In recent years there has been a significant paradigm shift in pre-clinical drug metabolism studies. Most importantly, this has included a reduced reliance on animal models and increased use of human tissues (i.e. human liver microsomes and other subcellular fractions, primary culture of human hepatocytes, recombinant human enzymes/transgenic cell lines). During the pre-clinical phase of drug development such studies assess the metabolic stability, reaction phenotyping (elucidation of specific enzyme(s) involved in phase I and II metabolism), metabolic fingerprinting (identification and structural determination of the metabolic end products) and drug interaction issues pertaining to enzyme inhibition and induction. Such studies are now increasingly being used for qualitative and quantitative prediction of drug biotransformation in humans and in the identification of likely determinants of metabolism following drug administration to humans, including possible drug interactions. Results from a multitude of such experiments help in identifying/optimizing a lead compound and rejecting compounds that are likely to be problematic with regards to causing toxicity or adverse drug-drug interactions. Therefore, well designed in vitro methodologies are vital to reducing the number of human trials during the late stages of drug development., Upotreba eksperimentalnih životinja i in vitro modela životinjskog porekla u pretkliničkim studijama metabolizma lekova je u velikoj meri potisnuta in vitro eksperimentalnim modelima poreklom od humanih tkiva. Danas se najviše koriste komercijalno dostupni preparati ljudske jetre, kao što su rekombinantni enzimi/transgenske ćelijske linije, subcelularne frakcije (mikrozomi, citozol i S9 frakcija) i primarni hepatociti. Primenom ovih modela u toku pretkliničke faze razvoja novog leka ispituje se stepen metaboličke transformacije leka, vrši se fenotipizacija metaboličkih reakcija (identifikacija specifičnog/ih enzima uključenih u I i II fazu metabolizma leka), određivanje metaboličkog profila (metabolic fingerprinting - identifikacija i određivanje strukture krajnjih produkata metabolizma leka) i razmatra se potencijal za stupanje u interakcije sa drugim lekovima, sa aspekta inhibicije i indukcije metaboličkih enzima. Primena in vitro - in vivo korelacije uz dobro razumevanje farmakokinetičkih principa omogućava predviđanje metabolizma i interakcija lekova in vivo na osnovu dobijenih in vitro podataka. Rezultati brojnih in vitro eksperimenata imaju značajnu ulogu u identifikaciji/optimizaciji vodećeg kandidata za novi lek. Dobro dizajnirane in vitro studije omogućavaju smanjenje broja kliničkih ispitivanja kod ljudi, koja se sprovode u kasnijim fazama razvoja leka.", publisher = "Savez farmaceutskih udruženja Srbije, Beograd", journal = "Arhiv za farmaciju", title = "Role of metabolism in drug development: In vitro studies, Značaj izučavanja metabolizma u razvoju novih lekova - in vitro pristup", volume = "60", number = "4", pages = "353-372", url = "https://hdl.handle.net/21.15107/rcub_farfar_1448" }
Rakić-Ignjatović, A., Miljković, B., Ilić, M., Pokrajac, M.,& Prostran, M.. (2010). Role of metabolism in drug development: In vitro studies. in Arhiv za farmaciju Savez farmaceutskih udruženja Srbije, Beograd., 60(4), 353-372. https://hdl.handle.net/21.15107/rcub_farfar_1448
Rakić-Ignjatović A, Miljković B, Ilić M, Pokrajac M, Prostran M. Role of metabolism in drug development: In vitro studies. in Arhiv za farmaciju. 2010;60(4):353-372. https://hdl.handle.net/21.15107/rcub_farfar_1448 .
Rakić-Ignjatović, Anita, Miljković, Branislava, Ilić, Marija, Pokrajac, Milena, Prostran, Milica, "Role of metabolism in drug development: In vitro studies" in Arhiv za farmaciju, 60, no. 4 (2010):353-372, https://hdl.handle.net/21.15107/rcub_farfar_1448 .
Related items
Showing items related by title, author, creator and subject.
-
The effect of paclitaxel alone and in combination with cycloheximide on the frequency of premature centromere division in vitro / Efekat samog paklitaksela, i u kombinaciji sa cikloheksimidom, na učestalost prevremene centromerne deobe in vitro
Bajić, Vladan; Stanimirović, Zoran; Stevanović, Jevrosima; Milićević, Zorka; Živković, Lada; Potparević, Biljana (Srpsko biološko društvo, Beograd, i dr., 2010) -
In vitro assessment of antiproliferative action selectivity of dietary isothiocyanates for tumor versus normal human cells / In vitro ispitivanje selektivnosti antiproliferativnog dejstva dijetetskih izotiocijanata na tumorske u odnosu na normalne humane ćelije
Konić-Ristić, Aleksandra; Stanojković, Tatjana; Srdić-Rajić, Tatjana; Dilber, Sanda; Đorđević, Brižita; Stanković, Ivan; Juranić, Zorica (Vojnomedicinska akademija - Institut za naučne informacije, Beograd, 2016) -
Evaluation of antigenotoxic potential of salvianolic acid B with hydrogen peroxide on human peripheral blood leukocytes in vitro / Evaluacija antigenotoksičnog potencijala salvianolične kiseline B u prisustvu vodonik-peroksida na leukocitima periferne krvi in vitro
Janković, Milena; Živković, Lada; Pirković, Andrea; Topalović, Dijana; Dekanski, Dragana; Bajić, Vladan; Potparević, Biljana (Srpsko lekarsko društvo - Okružna podružnica Kragujevac, Kragujevac, 2017)